Immune activation may determine success of dual-target CAR T therapy in glioblastoma

Dual-target CAR T-cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall survival.

CSF of individuals who did not respond to the therapy exhibited a higher proportion of activated regulatory T cells (Tregs) and high baseline levels of immunosuppressive scavenger myeloid cells, according to new research from the Perelman School of Medicine and Abramson Cancer Center at the University of Pennsylvania, published in Cell. ...